Jonathan Y. An

Jonathan Y. An

Auto-generated profile, based on publicly available information

Jonathan Y. An

Department of Oral Health Sciences, School of Dentistry University of Washington Seattle Washington USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2020 in eLife
Verified
Journal Article
Open access
JAJonathan Y An
Jonathan Y An
KKKristopher A Kerns
Kristopher A Kerns
AOAndrew Ouellette
Andrew Ouellette
LRLaura Robinson
Laura Robinson
H. Douglas MorrisH. Douglas Morris
H. Douglas Morris
MKMatt Kaeberlein
Matt Kaeberlein
Periodontal disease is an age-associated disorder clinically defined by periodontal bone loss, inflammation of the specialized tissues that surround and support the tooth, and microbiome dysbiosis. Currently, there is no therapy for reversing periodontal disease, and treatment is generally restricted to preventive measures or tooth extraction. The FDA-approved drug rapamycin slows aging and extends lifespan in multiple organisms, including mice. Here, we demonstrate that short-term treatment with rapamycin rejuvenates the aged oral cavity of elderly mice, including regeneration of periodontal bone, attenuation of gingival and periodontal bone inflammation, and revertive shift of the oral microbiome toward a more youthful composition. This provides a geroscience strategy to potentially rejuvenate oral health and reverse periodontal disease in the elderly.

1 August 2017 in GeroScience
Verified
Journal Article
Closed access
PDF file
JAJonathan Y. An
Jonathan Y. An
EQEllen Quarles
Ellen Quarles
SMSurapat Mekvanich
Surapat Mekvanich
AKAlex Kang
Alex Kang
ALAnthony Liu
Anthony Liu
MKMatt Kaeberlein
Matt Kaeberlein

16 May 2023 in GeroScience
Verified
Journal Article
Closed access
PDF file
TKTammi L. Kaeberlein
Tammi L. Kaeberlein
AGAlan S. Green
Alan S. Green
GHGeorge Haddad
George Haddad
JHJohnny Hudson
Johnny Hudson
AIAnar Isman
Anar Isman
MKMatt Kaeberlein
Matt Kaeberlein

27 December 2017 in GeroScience
Verified
Journal Article
Closed access
PDF file
JAJonathan Y. An
Jonathan Y. An
RDRichard Darveau
Richard Darveau
MKMatt Kaeberlein
Matt Kaeberlein

26 February 2010 in Immunology Letters
Verified
Journal Article
Closed access
WCWhasun O. Chung
Whasun O. Chung
JAJonathan Y. An
Jonathan Y. An
LYLei Yin
Lei Yin
BHBeth M. Hacker
Beth M. Hacker
MRMaryam G. Rohani
Maryam G. Rohani
DDDennis H. DiJulio
Dennis H. DiJulio

28 October 2010 in BMC Immunology
Verified
Journal Article
Open access
PDF file
MRMaryam G Rohani
Maryam G Rohani
DDDennis H DiJulio
Dennis H DiJulio
JAJonathan Y An
Jonathan Y An
BHBeth M Hacker
Beth M Hacker
BDBeverly A Dale
Beverly A Dale
WCWhasun O Chung
Whasun O Chung
Background: Protease-Activated Receptors (PARs), members of G-protein-coupled receptors, are activated by proteolytic activity of various proteases. Activation of PAR1 and PAR2 triggers innate immune responses in human oral keratinocytes (HOKs), but the signaling pathways downstream of PAR activation in HOKs have not been clearly defined. In this study, we aimed to determine if PAR1- and PAR2-mediated signaling differs in the induction of innate immune markers CXCL3, CXCL5 and CCL20 via ERK, p38 and PI3K/Akt. Results: Our data show the induction of innate immunity by PAR1 requires both p38 and ERK MAP kinases, while PAR2 prominently signals via p38. However, inhibition of PI3K enhances expression of innate immune markers predominantly via suppressing p38 phosphorylation signaled by PAR activation. Conclusion: Our data indicate that proteases mediating PAR1 and PAR2 activation differentially signal via MAP kinase cascades. In addition, the production of chemokines induced by PAR1 and PAR2 is suppressed by PI3K/Akt, thus keeping the innate immune responses of HOK in balance. The results of our study provide a novel insight into signaling pathways involved in PAR activation.